Cardiovascular Safety of Urate Lowering Therapies

Area of Science:

• Cardiovascular Medicine
• Rheumatology
• Pharmacology

Background:

• Gout is associated with increased cardiovascular (CV) risk, potentially linked to hyperuricemia, oxidative stress, and inflammation.
• The precise mechanisms connecting gout and CV disease remain under investigation.
• Existing research on urate-lowering treatment (ULT) and CV outcomes presents conflicting findings.

Purpose of the Study:

• To review the cardiovascular effects of urate-lowering treatments (ULTs).
• To discuss the comparative cardiovascular safety profiles of different ULT agents.
• To evaluate the impact of ULT on cardiovascular risk and mortality in patients with gout.

Main Methods:

• Review of existing literature, including meta-analyses of randomized controlled trials (RCTs).
• Discussion of findings from recent trials, such as the CARES trial comparing febuxostat and allopurinol.
• Analysis of potential mechanisms linking gout, ULT, and cardiovascular risk.

Main Results:

• Meta-analyses suggest potential CV benefits with allopurinol, but high-quality trials specifically in gout patients are limited.
• The CARES trial provided new data on the comparative CV safety of febuxostat and allopurinol.
• It remains uncertain if ULT effectively reduces CV risk in individuals with gout or hyperuricemia.

Conclusions:

• The role of ULT in modifying CV risk in gout patients requires further clarification.
• Mechanisms beyond simple urate reduction or xanthine oxidase inhibition may influence CV outcomes with ULT.
• Ongoing randomized controlled trials are expected to provide more definitive evidence on ULT's CV effects.